Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 15, Issue 1, 1996, Pages 30-37

  Quereda, C ^a   Polanco, A M ^a   Giner, C ^a   Sanchez Sousa A ^a   Pereira, E ^a   Navas, E ^a   Fortun J ^a   Guerrero, A ^a   Baquero, F ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE;

ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEDICAL DECISION MAKING; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; STRAIN DIFFERENCE; THRUSH; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS, ORAL; DRUG RESISTANCE, MICROBIAL; FEMALE; FLUCONAZOLE; HIV INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PHARYNGEAL DISEASES;

EID: 0030058868     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01586182     Document Type: Article

References (47)

1. Selik RM, Starcher ET, Curran JW: Opportunistic diseases reported in AIDS patients: frequencies, associations, trends. AIDS 1988, 1: 175-182.
2. Dupont B, Drouhet E: Fluconazole in the management of oropharyngeal candidiasis in a predominantly HIV antibody positive group of patients. Journal of Medical and Veterinary Mycology 1988, 26: 67-71.
3. Larsen RA: Azoles in AIDS. Journal of Infectious Diseases 1990, 162: 727-730.
4. Hay RJ: Overview of studies of fluconazole in oropharyngeal candidiasis. Reviews of Infectious Diseases 1990, 12, Supplement 3: 334-337.
5. Gil A, Lavilla P, Valencia E, Pintado V, Dupla M, Khamashta MA, Garcia-Puig J, Ortiz-Vazquez J: Safety and efficacy of fluconazole treatment for Candida oesophagitis in AIDS. Postgraduate Medical Journal 1991, 67: 548-552.
6. De Wit S, Urbain D, Rahir F, Weerts D, Clumeck N: Efficacy of oral fluconazole in the treatment of AIDS associated oesophageal candidiasis. European Journal of Clinical Microbiology & Infectious Diseases 1991, 10: 503-505.
7. Humphrey MJ, Jevons S, Tarbit MH: Pharmacokinetic evaluation of UK-49858, a metabolically stable triazole antifungal drug, in animals and humans. Journal of Antimicrobial Chemotherapy 1985, 28: 648-653.
8. Graybill JR: New antifungal agents. European Journal of Clinical Microbiology & Infectious Diseases 1989, 8: 402-412.
9. Grant SM, Clissold SP: Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990, 39: 877-916.
10. Morrow JD: Fluconazole: a new triazole antifungal agent. American Journal of Medical Sciences 1991, 302: 129-132.
11. Dronda F, Rodriguez-Tudela JL, Mera P. Martínez-Suárez J: Esofagitis por Candida albicans resistente a fluconazol: fracaso terapéutico y correlación in vitro. Medicina Clínica 1992, 5: 199.
12. Boken DJ, Swindells S, Rinaldi MG: Fluconazole-resistant Candida albicans. Clinical Infectious Diseases 1993, 17: 1018-1021.
13. Odds FC: Laboratory test for the activity of imidazole and triazole antifungal agents in vitro. Seminars in Dermatology 1985, 4: 260-270.
14. Willocks L, Leen CLS, Brettle RP, Urquhart D, Russell TB, Milne LJR: Fluconazole resistance in AIDS patients. Journal of Antimicrobial Chemotherapy 1991, 28: 937-939.
15. Mazuelos M: Situación actual de los estudios de sensibilidad a antifúngicos. Enfermedades Infecciosas y Microbiologia Clínica 1992, 10: 366-371.
16. Rex JH, Rinaldi MG, Pfaller MA: Resistance of Candida species to fluconazole. Antimicrobial Agents and Chemotherapy 1995, 39: 40-44.
17. Espinel-Ingroff A, Shadomy S: In vitro and in vivo evaluation of antifungal agents. European Journal of Clinical Microbiology & Infectious Diseases 1989, 8: 352-361.
18. Polanco AM, Rodríguez-Tudela JL, Baquero F, Sánchez-Sousa A, Martínez-Suarez J: Improved method of determining the susceptibility of Candida albicans to fluconazole. Journal of Antimicrobial Chemotherapy 1995, 35: 155-159.
19. Espinel-Ingroff A, Kish CW, Kerkering TM, Fromtling RA, Bartizal K, Galgiani JN, Villareal K, Pfaller MA, Gerarden T, Rinaldi MG, Fothergill A: Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. Journal of Clinical Microbiology 1992, 30: 3138-3145.
20. Rodríguez-Tudela JL, Martínez-Suarez JV: Improved medium for fluconazole susceptibility testing of Candida albicans. Antimicrobial Agents and Chemotherapy 1994, 38: 45-48.
21. Pfaller MA, Burmeister L, Bartlett MS, Rinaldi MG: Multicenter evaluation of four methods of yeast inoculum preparation. Journal of Clinical Microbiology 1988, 26: 1437-1441.
22. Galgiani JN, Stevens DA: Antimicrobial susceptibility testing of yeast: a turbidimetric technique independent of inoculum size. Antimicrobial Agents and Chemotherapy 1976, 10: 721-726.
23. National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing for yeasts. Proposed standard M27-P. NCCLS, Villanova, PA, 1992.
24. Klein RS, Harris CA, Small CB, Moll B, Lesser M, Friedland GH: Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. New England Journal of Medicine 1984, 311: 354-358.
25. Barchiesi F, Giacometti A, Azzeni D, Branchesi P, Crescen G, Ancari F, Scalise G: Fluconazole and ketoconazole in the treatment of oral and esophageal candidiasis in AIDS patients. Journal of Chemotherapy 1992, 4: 381-386.
26. Pons V, Greenspan D, Debruin M: Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. Journal of the Acquired Immune Deficiency Syndrome 1993, 6: 1311-1316.
27. Warnock D, Johnson EM, Richardson MD, Vickers CFH: Modified response to ketoconazole of Candida albicans from a treatment failure. Lancet 1983, i: 642-643.
28. Johnson EM, Richardson MD, Warnock D: In vitro resistance to imidazole antifungals in Candida albicans. Journal of Antimicrobial Chemotherapy 1984, 13: 547-558.
29. Ryley JF, Wilson RG, Barrett-Bee KJ: Azole resistance in Candida albicans. Journal of Medical and Veterinary Mycology 1984, 22: 53-63.
30. Tavitian A, Raufman JP, Rosenthal LE, Weber J, Weber CA, Dincsoy HP: Ketoconazole-resistant Candida esophagitis in patients with acquired immunodeficiency syndrome. Gastroenterology 1986, 90: 443-445.
31. Warnock DW, Burke J, Cope NJ, Johnson EM, Fraunhofer NA, Williams EW: Fluconazole resistance in Candida glabrata. Lancet 1988, ii: 1310.
32. Bluhm CH, Bickerstaff CA, Holt S: Refractory esophageal candidiasis in acquired immunodeficiency syndrome (AIDS). American Journal of Gastroenterology 1989, 85: 470-480.
33. Chavanet P, Lopez J, Grappin M, Bonnin A, Duong M, Waldner A, Buisson M, Camerlynck P, Portier H: Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients. AIDS 1994, 8: 945-950.
34. Sanguinetti A, Carmichael K, Campbell K: Fluconazole-resistant Candida albicans after long-term suppressive therapy. Archives of Internal Medicine 1993, 153: 1122-1124.
35. Diz P, Campo A, Miralles C, Otero I, Iglesias I, Martínez C: Candidosis oroesofágica resistente al fluconazol en pacientes con sida. Enfermedades Infecciosas y Microbiología Clinica 1993, 11: 6-39.
36. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R: Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. New England Journal of Medicine 1991, 325: 1274-1277.
37. Persons DA, Laughlin ML, Tanner D, Perfect J, Gockerman JP, Hathorn J: Fluconazole and Candida krusei fungemia. New England Journal of Medicine 1991, 325: 1315.
38. Akova M, Akalin HE, Uzun O, Gur D: Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. European Journal of Clinical Microbiology & Infectious Diseases 1991, 10: 598-599.
39. Johnson EM, Warnock DW, Lucker J, Parker SR, Scully C: Emergence of drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. Journal of Antimicrobial Chemotherapy 1995, 35: 104-114.
40. Newman SL, Flanigan TP, Fisher A, Rinaldi MG, Stein M, Vigilante K: Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clinical Infectious Diseases 1994, 19: 684-686.
41. Parente F, Cernuschi M, Rizzardini G, Lazzarin A, Valsecchi L, Vianchi-Porro G: Opportunistic infections of esophagus not responding to oral systemic antifungals in patients with AIDS: their frequency and treatment. American Journal of Gastroenterology 1991, 86: 1729-2734.
42. Ansari AM, Gould IM, Douglas JG: High dose oral fluconazole for oropharyngeal candidosis in AIDS. Journal of Antimicrobial Chemotherapy 1990, 25: 720-721.
43. Rex H, Hanson LH, Arrantea MA, Stevens DA, Bennett JE: Standardization of a fluconazole bioassay and correlation of results with those obtained by high pressure liquid chromatography. Antimicrobial Agents and Chemotherapy 1991, 35: 846-850.
44. Baily GG, Perry FM, Denning DW, Mandal BK: Fluconazole-resistant candidosis in an HIV cohort. AIDS 1994, 8: 787-792.
45. Horn CA, Washburn RG, Givner LB, Peacock JE, Pegram PS: Azole-resistant oropharyngeal and esophageal candidiasis in patients with AIDS. AIDS 1995, 9: 533-534.
46. Rodriguez-Tudela JL, Martinez-Suarez JV, Dronda F, Laguna F, Chaves F, Valencia E: Correlation of in vitro susceptibility test results with clinical response: a study of azole therapy in eight patients. Journal of Antimicrobial Chemotherapy 1995, 35: 793-804.
47. Troillet N, Durussel C, Bille J, Glauser MP, Chave JP: Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. European Journal of Clinical Microbiology & Infectious Diseases 1993, 12: 911-915.